References
- Goodrum F. Human Cytomegalovirus Latency: approaching the Gordian Knot. Annu Rev Virol. 2016;3:333–357. . Internet
- El Helou G, Razonable R. Letermovir for the prevention of cytomegalovirus infection and disease in transplant recipients: an evidence-based review. Infect Drug Resist. [ Internet]. 2019;12:1481–1491. Available from: https://www.dovepress.com/letermovir-for-the-prevention-of-cytomegalovirus-infection-and-disease-peer-reviewed-article-IDR.
- Meesing A, Razonable RR. New Developments in the Management of Cytomegalovirus Infection After Transplantation. Drugs. [ Internet]. 2018;78:1085–1103.
- Griffiths PD, Nichols G, Lundgren J, et al. Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials: table 1. Clin Infect Dis. 2016;64:87–91.
- Razonable RR, Humar A. Cytomegalovirus in solid organ transplant recipients—guidelines of the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. [ Internet]. 2019;13:e13512.10.1111/ajt.12103.
- Razonable RR. Immune-based therapies for cytomegalovirus infection. Immunotherapy. 2010;2:117–130. . Internet
- Hodson EM, Jones CA, Strippoli GF, et al. Immunoglobulins, vaccines or interferon for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev. [ Internet]. 2007. DOI:10.1002/14651858.CD005129.pub2.
- Zarrouk K, Piret J, Boivin G. Herpesvirus DNA polymerases: structures, functions and inhibitors. Virus Res. [ Internet]. 2017;234:177–192. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0168170216306876.
- Goldner T, Hewlett G, Ettischer N, et al. The Novel Anticytomegalovirus Compound AIC246 (Letermovir) Inhibits Human Cytomegalovirus Replication through a Specific Antiviral Mechanism That Involves the Viral Terminase. J Virol. [ Internet]. 2011;85:10884–10893. .
- Williams SL, Hartline CB, Kushner NL, et al. In Vitro Activities of Benzimidazole D- and L-Ribonucleosides against Herpesviruses. Antimicrob Agents Chemother. [ Internet]. 2003;47:2186–2192. .
- Biron KK, Harvey RJ, Chamberlain SC, et al. Potent and Selective Inhibition of Human Cytomegalovirus Replication by 1263W94, a Benzimidazole L-Riboside with a Unique Mode of Action. Antimicrob Agents Chemother. [ Internet]. 2002;46:2365–2372. .
- Letermovir (Prevymis). FDA Medical Review [ Internet]. 2017. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209939Orig1s000,209940Orig1s000Approv.pdf.
- Turner N, Strand A, Grewal DS, et al. Use of Letermovir as Salvage Therapy for Drug-Resistant Cytomegalovirus Retinitis. Antimicrob Agents Chemother. [ Internet]. 2019;63:1–6. .
- Chong PP, Teiber D, Prokesch BC, et al. Letermovir successfully used for secondary prophylaxis in a heart transplant recipient with ganciclovir-resistant cytomegalovirus syndrome (UL97 mutation). Transpl Infect Dis [Internet]. 2018;20:e12965.
- Stoelben S, Arns W, Renders L, et al. Preemptive treatment of Cytomegalovirus infection in kidney transplant recipients with letermovir: results of a Phase 2a study. Transpl Int. 2014;27:77–86.
- Kaul DR, Stoelben S, Cober E, et al. First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246. Am J Transplant. [ Internet]. 2011;11:1079–1084. .
- Cherrier L, Nasar A, Goodlet KJ, et al. Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection. Am J Transplant. [ Internet]. 2018. DOI:10.1111/ajt.15135.
- Lalezari JP, Aberg JA, Wang LH, et al. Phase I Dose Escalation Trial Evaluating the Pharmacokinetics, Anti-Human Cytomegalovirus (HCMV) Activity, and Safety of 1263W94 in Human Immunodeficiency Virus-Infected Men with Asymptomatic HCMV Shedding. Antimicrob Agents Chemother. [ Internet]. 2002;46:2969–2976. .
- Sprague K, Klein J, Petersen F, et al. Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study. Blood. 2008;111:5403–5410.
- Marty FM, Ljungman P, Papanicolaou GA, et al. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infect Dis. [ Internet]. 2011;11:284–292. Available from: https://linkinghub.elsevier.com/retrieve/pii/S147330991170024X.
- Winston DJ, Saliba F, Blumberg E, et al. Efficacy and Safety of Maribavir Dosed at 100 mg Orally Twice Daily for the Prevention of Cytomegalovirus Disease in Liver Transplant Recipients: A Randomized, Double-Blind, Multicenter Controlled Trial. Am J Transplant [Internet]. 2012;12:3021–3030.
- Avery RK, Marty FM, Strasfeld L, et al. Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients. Transpl Infect Dis [Internet]. 2010;12:489–496.
- Alain S, Revest M, Veyer D, et al. Maribavir Use in Practice for Cytomegalovirus Infection in French Transplantation Centers. Transplant Proc. [ Internet]. 2013;45:1603–1607. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0041134513001346.
- Biron KK, Stanat SC, Sorrell JB, et al. Metabolic activation of the nucleoside analog 9-[(2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine in human diploid fibroblasts infected with human cytomegalovirus. Proc Natl Acad Sci. [ Internet]. 1985;82:2473–2477. .
- ValcyteTM (valganciclovir HCl tablets) [package insert]. Nutley, NJ: Roche Laboratoires Inc; 2001.
- GANCICLOVIR- ganciclovir capsule [package insert]. Jacksonville, FL: Ranbaxy Pharmaceuticals Inc.; 2011.
- GANCICLOVIR INJECTION [package insert]. Lenoir, NC: Exela pharma sciences; 1989.
- Harbison MA, De Girolami PC, Jenkins RL, et al. Ganciclovir therapy of severe cytomegalovirus infections in solid-organ transplant recipients. Transplantation. [ Internet]. 1988;46:82–88. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2839916.
- Ritchie BM, Barreto JN, Barreto EF, et al. Relationship of Ganciclovir Therapeutic Drug Monitoring with Clinical Efficacy and Patient Safety. Antimicrob Agents Chemother. [ Internet]. 2019;63. DOI:10.1128/AAC.01855-18.
- Wiltshire H, Paya CV, Pescovitz MD, et al. Pharmacodynamics of Oral Ganciclovir and Valganciclovir in Solid Organ Transplant Recipients. Transplantation. [ Internet]. 2005;79:1477–1483. Available from: https://insights.ovid.com/crossref?an=00007890-200506150-00004.
- Walker JK, Scholz LM, Scheetz MH, et al. Leukopenia Complicates Cytomegalovirus Prevention After Renal Transplantation With Alemtuzumab Induction. Transplantation. [ Internet]. 2007;83:874–882. Available from: https://insights.ovid.com/crossref?an=00007890-200704150-00006.
- Takahata M, Hashino S, Nishio M, et al. Occurrence of adverse events caused by valganciclovir as pre-emptive therapy for cytomegalovirus infection after allogeneic stem cell transplantation is reduced by low-dose administration. Transpl Infect Dis [Internet]. 2015;17:810–815.
- Padullés A, Colom H, Bestard O, et al. Contribution of Population Pharmacokinetics to Dose Optimization of Ganciclovir-Valganciclovir in Solid-Organ Transplant Patients. Antimicrob Agents Chemother. 2016;60:1992–2002.
- Wiltshire H, Paya CV, Pescovitz MD, et al. Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients. Transplantation. 2005;79:1477–1483.
- Danesi R, Del Tacca M. Hematologic toxicity of immunosuppressive treatment. Transplant Proc. [ Internet]. 2004;36:703–704. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0041134504002441.
- Manuel O, Venetz J-P, Fellay J, et al. Efficacy and safety of universal valganciclovir prophylaxis combined with a tacrolimus/mycophenolate-based regimen in kidney transplantation. Swiss Med Wkly. [ Internet]. 2007;137:669–676. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18058275.
- Danziger-Isakov L, Baillie MG. Hematologic complications of anti-CMV therapy in solid organ transplant recipients. Clin Transplant. 2009;23:295–304.
- Limaye AP, Corey L, Koelle DM, et al. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet. [ Internet]. 2000;356:645–649. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0140673600026076.
- Humar A. Cytomegalovirus Prevention: prophylaxis and Preemptive Therapy. Transplantation. [ Internet]. 2007;84:S11–S14. Available from: https://insights.ovid.com/crossref?an=00007890-200709271-00004.
- Limaye AP, Raghu G, Koelle DM, et al. High Incidence of Ganciclovir‐Resistant Cytomegalovirus Infection among Lung Transplant Recipients Receiving Preemptive Therapy. J Infect Dis. [ Internet]. 2002;185:20–27. .
- Singh N. Preemptive Therapy Versus Universal Prophylaxis with Ganciclovir for Cytomegalovirus in Solid Organ Transplant Recipients. Clin Infect Dis [Internet]. 2001;32:742–751.
- Bhorade SM, Lurain NS, Jordan A, et al. Emergence of ganciclovir-resistant cytomegalovirus in lung transplant recipients. J Heart Lung Transplant. [ Internet]. 2002;21:1274–1282. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12490272.
- Crumpacker CS. Ganciclovir. Wood AJJ, editor. N Engl J Med. 1996;335:721–729. . Internet
- Turgeon N, Hovingh GK, Fishman JA, et al. Safety and efficacy of granulocyte colony-stimulating factor in kidney and liver transplant recipients. Transpl Infect Dis. [ Internet]. 2000;2:15–21. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11429005.
- Peddi VR, Hariharan S, Schroeder TJ, et al. Role of granulocyte colony stimulating factor (G-CSF) in reversing neutropenia in renal allograft recipients. Clin Transplant. [ Internet]. 1996;10:20–23. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8652892.
- Iltar U, Salim O, Küpesiz A. Severe thrombocytopenia related to filgrastim mobilization in a healthy donor. Transfus Apher Sci. [ Internet]. 2018;57:777–778. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1473050218303367.
- Slater MB, Gruneir A, Rochon PA, et al. Identifying High-Risk Medications Associated with Acute Kidney Injury in Critically Ill Patients: A Pharmacoepidemiologic Evaluation. Pediatr Drugs [Internet]. 2017;19:59–67.
- Berns JS, Cohen RM, Stumacher RJ, et al. Renal aspects of therapy for human immunodeficiency virus and associated opportunistic infections. J Am Soc Nephrol. [ Internet]. 1991;1:1061–1080. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0026128545&partnerID=40&md5=e702824ec4b5a190e728cdb653b61463.
- Lewis RA. Morbidity and Toxic Effects Associated With Ganciclovir or Foscarnet Therapy in a Randomized Cytomegalovirus Retinitis Trial. Arch Intern Med. 1995;155:65. . Internet
- Pescovitz MD. Absence of teratogenicity of oral ganciclovir used during early pregnancy in a liver transplant recipient. Transplantation. [ Internet]. 1999;67:758–759. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10096536.
- Miller BW, Howard TK, Goss JA, et al. Renal transplantation one week after conception. Transplantation. [ Internet]. 1995;60:1353–1354. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8525535.
- EMA. Annex III. 2018. Available from: https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-10/eudralex_vol10_chapter4_guidance-conduct_annex3.pdf
- Jacobsen T, Sifontis N. Drug interactions and toxicities associated with the antiviral management of cytomegalovirus infection. Am J Heal Pharm. 2010;67:1417–1425. . Internet
- Cimoch PJ, Lavelle J, Pollard R, et al. Pharmacokinetics of oral ganciclovir alone and in combination with zidovudine, didanosine, and probenecid in HIV-infected subjects. J Acquir Immune Defic Syndr Hum Retrovirol. [ Internet]. 1998;17:227–234. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9495222.
- Manischewitz JF, Quinnan GV, Lane HC, et al. Synergistic effect of ganciclovir and foscarnet on cytomegalovirus replication in vitro. Antimicrob Agents Chemother. [ Internet]. 1990;34:373–375. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2158278.
- Manion DJ, Vibhagool A, Chou TC, et al. Susceptibility of human cytomegalovirus to two-drug combinations in vitro. Antivir Ther. [ Internet]. 1996;1:237–245. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11324826.
- Mattes FM, Hainsworth EG, Geretti A, et al. A Randomized, Controlled Trial Comparing Ganciclovir to Ganciclovir Plus Foscarnet (Each at Half Dose) for Preemptive Therapy of Cytomegalovirus Infection in Transplant Recipients. J Infect Dis [Internet]. 2004;189:1355–1361.
- Bacigalupo A, Bregante S, Tedone E, et al. Combined foscarnet-ganciclovir treatment for cytomegalovirus infections after allogeneic hemopoietic stem cell transplantation. Transplantation. [ Internet]. 1996;62:376–380. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8779686.
- Mylonakis E, Kallas WM, Fishman JA. Combination Antiviral Therapy for Ganciclovir‐Resistant Cytomegalovirus Infection in Solid‐Organ Transplant Recipients. Clin Infect Dis. 2002;34:1337–1341. . Internet
- Jacobson MA, Drew WL, Feinberg J, et al. Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis in patients with AIDS. J Infect Dis. [ Internet]. 1991;163:1348–1351. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1645385.
- Razonable RR. Drug-resistant cytomegalovirus. Curr Opin Organ Transplant. [ Internet]. 2018;1. Available from: http://insights.ovid.com/crossref?an=00075200-900000000-99129
- Fisher CE, Knudsen JL, Lease ED, et al. Risk Factors and Outcomes of Ganciclovir-Resistant Cytomegalovirus Infection in Solid Organ Transplant Recipients. Clin Infect Dis. [ Internet]. 2017;65:57–63. Available from: https://academic.oup.com/cid/article/65/1/57/3093136.
- Majeed A, Latif A, Kapoor V, et al. Resistant Cytomegalovirus Infection in Solid-organ Transplantation: single-center Experience, Literature Review of Risk Factors, and Proposed Preventive Strategies. Transplant Proc. [ Internet]. 2018;50:3756–3762. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0041134518302628.
- Chrisp P, Clissold SP. Foscarnet. Drugs. 1991;41:104–129. . Internet
- FOSCAVIR® (foscarnet sodium) [Package insert]. Graz, Austria: Clinigen healthcare Ltd; 2017.
- Deray G, Martinez F, Katlama C, et al. Foscarnet Nephrotoxicity: mechanism, Incidence and Prevention. Am J Nephrol. [ Internet]. 1989;9:316–321. Available from: https://www.karger.com/Article/FullText/167987.
- Maurice-Estepa L, Daudon M, Katlama C, et al. Identification of crystals in kidneys of AIDS patients treated with foscarnet. Am J Kidney Dis. [ Internet]. 1998;32:392–400. Available from: https://linkinghub.elsevier.com/retrieve/pii/S027263869800242X.
- Vial R, Zandotti C, Alain S, et al. Brincidofovir Use after Foscarnet Crystal Nephropathy in a Kidney Transplant Recipient with Multiresistant Cytomegalovirus Infection. Case Rep Transplant. [ Internet]. 2017;2017:1–7. Available from: https://www.hindawi.com/journals/crit/2017/3624146/.
- Justrabo E, Zanetta G, Martin L, et al. Irreversible glomerular lesions induced by crystal precipitation in a renal transplant after foscarnet therapy for cytomegalovirus infection. Histopathology. [ Internet]. 1999;34:365–369. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10231404.
- Zanetta G, Maurice-Estepa L, Mousson C, et al. Foscarnet-induced crystalline glomerulonephritis with nephrotic syndrome and acute renal failure after kidney transplantation. Transplantation. [ Internet]. 1999;67:1376–1378. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10360595.
- Tischler V, Schuurmans MM, Boehler A, et al. Crystal precipitation and granulomatous inflammation in multiple organs after foscarnet therapy in a lung transplant recipient. J Hear Lung Transplant. [ Internet]. 2012;31:1037–1040. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1053249812011138.
- Philipponnet C, Michel P-A, Daudon M, et al. Intravascular Foscarnet Crystal Precipitation Causing Multiorgan Failure. Am J Kidney Dis. [ Internet]. 2015;65:152–155. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0272638614011573.
- Iwami D, Ogawa Y, Fujita H, et al. Successful treatment with foscarnet for ganciclovir-resistant cytomegalovirus infection in a kidney transplant recipient: A case report. Nephrol [Internet]. 2016;21:63–66.
- Youle MS, Clarbour J, Gazzard B, et al. SEVERE HYPOCALCAEMIA IN AIDS PATIENTS TREATED WITH FOSCARNET AND PENTAMIDINE. Lancet. [ Internet]. 1988;331:1455–1456. Available from: https://linkinghub.elsevier.com/retrieve/pii/S014067368892260X.
- Fan-Havard P, Sanchorawala V, Oh J, et al. Concurrent Use of Foscarnet and Ciprofloxacin May Increase the Propensity for Seizures. Ann Pharmacother [Internet]. 1994;28:869–872.
- Fégueux S, Salmon D, Picard C, et al. Penile ulcerations with foscarnet. Lancet. [ Internet]. 1990;335:547–548. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1968562.
- Risk of ulceration from foscarnet. Nurs Stand [Internet]. 1990;4:16.
- Torres T, Fernandes I, Sanches M, et al. Foscarnet-induced penile ulceration. Acta Dermatovenerol Alp Pannonica Adriat. [ Internet]. 2011;20:39–40. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21879205.
- Moyle G, Barton S, Gazzard BG. Penile ulceration with foscarnet therapy. AIDS. [ Internet]. 1993;7:140–141. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8382924.
- Adalsteinsson JA, Pan M, Kaushik S, et al. Foscarnet-induced genital lesions: an overview with a case report. Dermatol Reports. [ Internet]. 2018;10. Available from: https://www.pagepress.org/journals/index.php/dr/article/view/7749
- El Chaer F, Shah DP, Chemaly RF. How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients. Blood. 2016;128:2624–2636.
- Cihlar T, Chen MS. Identification of enzymes catalyzing two-step phosphorylation of cidofovir and the effect of cytomegalovirus infection on their activities in host cells. Mol Pharmacol. [ Internet]. 1996;50:1502–1510. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8967971.
- Xiong X, Smith JL, Kim C, et al. Kinetic analysis of the interaction of cidofovir diphosphate with human cytomegalovirus DNA polymerase. Biochem Pharmacol. [ Internet]. 1996;51:1563–1567. Available from: http://linkinghub.elsevier.com/retrieve/pii/0006295296001001.
- Ortiz A, Justo P, Sanz A, et al. Tubular cell apoptosis and cidofovir-induced acute renal failure. Antivir Ther. [ Internet]. 2005;10:185–190. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15751777.
- Ho ES, Lin DC, Mendel DB, et al. Cytotoxicity of antiviral nucleotides adefovir and cidofovir is Induced by the expression of human renal organic anion transporter 1. J Am Soc Nephrol. [ Internet]. 2000;11:383–393. Available from: http://jasn.asnjournals.org/content/11/3/383.full.
- Nieskens TTG, Peters JGP, Schreurs MJ, et al. A Human Renal Proximal Tubule Cell Line with Stable Organic Anion Transporter 1 and 3 Expression Predictive for Antiviral-Induced Toxicity. Aaps J. 2016;18:465–475.
- Kazory A, Singapuri S, Wadhwa A, et al. Simultaneous development of Fanconi syndrome and acute renal failure associated with cidofovir. J Antimicrob Chemother. [ Internet]. 2007;60:193–194. Available from: http://academic.oup.com/jac/article/60/1/193/730664/Simultaneous-development-of-Fanconi-syndrome-and.
- Vistide (cidofovir) [package insert]. Foster City, CA: Gilead; 2010. Available from: https://www.gilead.com/-/media/files/pdfs/medicines/other/vistide/vistide.pdf.
- Chavez-de la Paz E, Arevalo JF, Kirsch LS, et al. Anterior nongranulomatous uveitis after intravitreal HPMPC (cidofovir) for the treatment of cytomegalovirus retinitis. Analysis and prevention. Ophthalmology. [ Internet]. 1997;104:539–544. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9082286.
- Davis JL, Taskintuna I, Freeman WR, et al. Iritis and hypotony after treatment with intravenous cidofovir for cytomegalovirus retinitis. Arch Ophthalmol (Chicago, Ill 1960). [ Internet]. 1997;115:733–737. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9194724.
- Friedberg DN. Hypotony and visual loss with intravenous cidofovir treatment of cytomegalovirus retinitis. Arch Ophthalmol (Chicago, Ill 1960). [ Internet]. 1997;115:801–802. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9194736.
- Akler ME, Johnson DW, Burman WJ, et al. Anterior uveitis and hypotony after intravenous cidofovir for the treatment of cytomegalovirus retinitis. Ophthalmology. [ Internet]. 1998;105:651–657. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0161642098940192.
- Labetoulle M, Goujard C, Frau E, et al. Cidofovir ocular toxicity is related to previous ocular history. AIDS. [ Internet]. 2000;14. Available from: https://journals.lww.com/aidsonline/Fulltext/2000/03310/Cidofovir_ocular_toxicity_is_related_to_previous.22.aspx
- Moorthy RS, Valluri S. Ocular toxicity associated with systemic drug therapy. Curr Opin Ophthalmol. 1999;10:438–446.
- Taskintuna I, Banker AS, Rao NA, et al. An animal model for cidofovir (HPMPC) toxicity: intraocular pressure and histopathologic effects. Exp Eye Res. [ Internet]. 1997;64:795–806. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9245910.
- Taskintuna I, Rahhal FM, Rao NA, et al. Adverse events and autopsy findings after intravitreous cidofovir (HPMPC) therapy in patients with acquired immune deficiency syndrome (AIDS). Ophthalmology. [ Internet]. 1997;104:1827–1836; discussion 1836–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9373113.
- Uchio E. [New medical treatment for viral conjunctivitis]. Nippon Ganka Gakkai Zasshi. [ Internet]. 2005;109:962–984; discussion 985. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16408491.
- Inoue H, Sonoda K, Ishikawa M, et al. Clinical Evaluation of Local Ocular Toxicity in Candidate Anti-Adenoviral Agents in vivo. Ophthalmologica. [ Internet]. 2009;223:233–238. Available from: https://www.karger.com/Article/FullText/205585.
- Jacobson MA, Wilson S, Stanley H, et al. Phase I Study of Combination Therapy with Intravenous Cidofovir and Oral Ganciclovir for Cytomegalovirus Retinitis in Patients with AIDS. Clin Infect Dis. 1999;28:528–533.
- Lalezari JP, Kuppermann BD. Clinical experience with cidofovir in the treatment of cytomegalovirus retinitis. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;14(Suppl 1):S27–31.
- Tippin TK, Morrison ME, Brundage TM, et al. Brincidofovir Is Not A Substrate For The Human Organic Anion Transporter 1 (Oat1). Ther Drug Monit. [ Internet]. 2016;1. Available from: http://insights.ovid.com/crossref?an=00007691-900000000-99133
- Hostetler KY. Synthesis and Early Development of Hexadecyloxypropyl-cidofovir: an Oral Antipoxvirus Nucleoside Phosphonate. Viruses. 2010;2:2213–2225.
- Marty FM, Winston DJ, Rowley SD, et al. CMX001 to Prevent Cytomegalovirus Disease in Hematopoietic-Cell Transplantation. N Engl J Med. 2013;369:1227–1236.
- Marty FM, Winston DJ, Chemaly RF, et al. A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Oral Brincidofovir for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. [ Internet]. 2019;25:369–381. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1083879118306050.
- Detweiler CJ, Mueller SB, Sung AD, et al. Brincidofovir (CMX001) Toxicity Associated With Epithelial Apoptosis and Crypt Drop Out in a Hematopoietic Cell Transplant Patient. J Pediatr Hematol Oncol. [ Internet]. 2018;40:e364–e368. Available from: http://insights.ovid.com/crossref?an=00043426-201808000-00027.
- Kreft A, Mottok A, Mesteri I, et al. Consensus diagnostic histopathological criteria for acute gastrointestinal graft versus host disease improve interobserver reproducibility. Virchows Arch. [ Internet]. 2015;467:255–263. .
- Papadimitriou JC, Cangro CB, Lustberg A, et al. Histologic Features of Mycophenolate Mofetil-Related Colitis: A Graft-Versus-Host Disease-Like Pattern. Int J Surg Pathol [Internet]. 2003;11:295–302.
- Selbst MK, Ahrens WA, Robert ME, et al. Spectrum of histologic changes in colonic biopsies in patients treated with mycophenolate mofetil. Mod Pathol. [ Internet]. 2009;22:737–743. Available from: http://www.nature.com/articles/modpathol200944.
- Marschall M, Stamminger T, Urban A, et al. In Vitro Evaluation of the Activities of the Novel Anticytomegalovirus Compound AIC246 (Letermovir) against Herpesviruses and Other Human Pathogenic Viruses. Antimicrob Agents Chemother. [ Internet]. 2012;56:1135–1137. .
- Chemaly RF, Ullmann AJ, Stoelben S, et al. Letermovir for Cytomegalovirus Prophylaxis in Hematopoietic-Cell Transplantation. N Engl J Med. [ Internet]. 2014;370:1781–1789. .
- Marty FM, Ljungman P, Chemaly RF, et al. Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation. N Engl J Med. [ Internet]. 2017:NEJMoa1706640. DOI:10.1056/NEJMoa1706640.
- Geswein L. Letermovir associated hepatic transaminitis: a case report. J. Oncol. Pharm. Pract. [ Internet]. 2019;25:1235–1238. Available from: http://journals.sagepub.com/doi/10.1177/1078155218783245.
- PREVYMISTM (letermovir) [Package insert]. Whitehouse Station, NJ: Merck Sharp & Dohme Corp; 2017.
- Kropeit D, von Richter O, Stobernack H-P, et al. Pharmacokinetics and Safety of Letermovir Coadministered With Cyclosporine A or Tacrolimus in Healthy Subjects. Clin Pharmacol Drug Dev [Internet]. 2018;7:9–21.
- Marshall WL, McCrea JB, Macha S, et al. Pharmacokinetics and Tolerability of Letermovir Coadministered With Azole Antifungals (Posaconazole or Voriconazole) in Healthy Subjects. J Clin Pharmacol [Internet]. 2018;58:897–904.
- Chou S. Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance. Antimicrob Agents Chemother. 2015;59:6588–6593. . Internet
- Prichard MN. Function of human cytomegalovirus UL97 kinase in viral infection and its inhibition by maribavir. Rev Med Virol. 2009;19:215–229.
- He Z, He YS, Kim Y, et al. The human cytomegalovirus UL97 protein is a protein kinase that autophosphorylates on serines and threonines. J Virol. 1997;71:405–411.
- Chou S, Marousek GI. Maribavir Antagonizes the Antiviral Action of Ganciclovir on Human Cytomegalovirus. Antimicrob Agents Chemother. 2006;50:3470–3472.
- Chou S, Ercolani RJ, Derakhchan K. Antiviral activity of maribavir in combination with other drugs active against human cytomegalovirus. Antiviral Res. [ Internet]. 2018;157:128–133. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0166354218303061.
- O’Brien MS, Markovich KC, Selleseth D, et al. In vitro evaluation of current and novel antivirals in combination against human cytomegalovirus. Antiviral Res. 2018;158:255–263.
- Malvezzi P, Jouve T, Rostaing L. Use of Everolimus-based Immunosuppression to Decrease Cytomegalovirus Infection After Kidney Transplant. Exp Clin Transplant. 2016;14:361–366.
- Brennan DC, Legendre C, Patel D, et al. Cytomegalovirus Incidence Between Everolimus Versus Mycophenolate in De Novo Renal Transplants: pooled Analysis of Three Clinical Trials. Am J Transplant. 2011;11:2453–2462.
- Pascual J, Royuela A, Fernández AM, et al. Role of mTOR inhibitors for the control of viral infection in solid organ transplant recipients. Transpl Infect Dis. 2016;18:819–831.
- Winston DJ, Young J-AH, Pullarkat V, et al. Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study. Blood. 2008;111:5403–5410.
- Pescovitz MD, Bloom R, Pirsch J, et al. A Randomized, Double-Blind, Pharmacokinetic Study of Oral Maribavir with Tacrolimus in Stable Renal Transplant Recipients. Am J Transplant. 2009;9:2324–2330.
- Strasfeld L, Lee I, Tatarowicz W, et al. Virologic Characterization of Multidrug‐Resistant Cytomegalovirus Infection in 2 Transplant Recipients Treated with Maribavir. J Infect Dis. 2010;202:104–108.
- Zolfaghari V, Ahmadi Simab S, Hasanzamani B, et al. The effect of cytomegalovirus infection on acute rejection in kidney transplanted patients. J Ren Inj Prev. [ Internet]. 2016;5:85–88. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27471740.
- von Willebrand E, Pettersson E, Ahonen J, et al. CMV infection, class II antigen expression, and human kidney allograft rejection. Transplantation. 1986;42:364–367.
- Akposso K, Rondeau E, Haymann JP, et al. Long-term prognosis of renal transplantation after preemptive treatment of cytomegalovirus infection. Transplantation. 1997;63:974–976.
- Eid AJ, Arthurs SK, Deziel PJ, et al. Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes. Clin Transplant. 2007;22:162–170.
- Bonaros N, Mayer B, Schachner T, et al. CMV-hyperimmune globulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients: a meta-analysis. Clin Transplant. 2007;070816071748001–???.
- Isada CM, Yen-Lieberman B, Lurain NS, et al. Clinical characteristics of 13 solid organ transplant recipients with ganciclovir-resistant cytomegalovirus infection. Transpl Infect Dis. 2002;4:189–194.
- Snydman DR, Werner BG, Heinze-Lacey B, et al. Use of Cytomegalovirus Immune Globulin to Prevent Cytomegalovirus Disease in Renal-Transplant Recipients. N Engl J Med [Internet]. 1987;317:1049–1054.
- Cayco AV, Perazella MA, Hayslett JP. Renal insufficiency after intravenous immune globulin therapy: a report of two cases and an analysis of the literature. J Am Soc Nephrol. [ Internet]. 1997;8:1788–1794. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9355083.
- Cantú TG, Hoehn-Saric EW, Burgess KM, et al. Acute renal failure associated with immunoglobulin therapy. Am J Kidney Dis. [ Internet]. 1995;25:228–234. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7847349.
- Hansen-Schmidt S, Silomon J, Keller F. Osmotic nephrosis due to high-dose immunoglobulin therapy containing sucrose (but not with glycine) in a patient with immunoglobulin A nephritis. Am J Kidney Dis. [ Internet]. 1996;28:451–453. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8804246.
- Tan E, Hajinazarian M, Bay W, et al. Acute renal failure resulting from intravenous immunoglobulin therapy. Arch Neurol. [ Internet]. 1993;50:137–139. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8431131.
- Winward DB, Brophy MT. Acute renal failure after administration of intravenous immunoglobulin: review of the literature and case report. Pharmacotherapy. [ Internet]. 1995;15:765–772. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8602385.
- RIGDON RH. RENAL LESIONS FOLLOWING THE INTRAVENOUS INJECTION OF A HYPERTONIC SOLUTION OF SUCROSE. Arch Intern Med. 1942;69:670. . Internet
- ANDERSON WAD, BETHEA WR. RENAL LESIONS FOLLOWING ADMINISTRATION OF HYPERTONIC SOLUTIONS OF SUCROSE. J Am Med Assoc. [ Internet]. 1940;114. DOI:10.1001/jama.1940.02810200011002.
- Epstein JS, Zoon KC. Important drug warning: immune Globulin Intravenous (human) (IGIV) products. Neonatal Netw. [ Internet]. 2000;19:60–62. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11949001.
- Dalakas MC. High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events. Neurology. [ Internet]. 1994;44:223–226. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8309562.
- Woodruff RK, Grigg AP, Firkin FC, et al. FATAL THROMBOTIC EVENTS DURING TREATMENT OF AUTOIMMUNE THROMBOCYTOPENIA WITH INTRAVENOUS IMMUNOGLOBULIN IN ELDERLY PATIENTS. Lancet. [ Internet]. 1986;328:217–218. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0140673686925110.
- Wolberg AS, Kon RH, Monroe DM, et al. Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations. Am J Hematol. [ Internet]. 2000;65:30–34. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10936860.
- Bertorini TE, Nance AM, Horner LH, et al. Complications of intravenous gammaglobulin in neuromuscular and other diseases. Muscle Nerve. [ Internet]. 1996;19:388–391. .
- Brannagan TH. Intravenous gammaglobulin (IVIg) for treatment of CIDP and related immune-mediated neuropathies. Neurology. 2002;59:S33–S40. . Internet
- Sekul EA. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med. [Internet]. 1994;121:259.
- Kato E. Administration of Immune Globulin Associated With Aseptic Meningitis. JAMA J Am Med Assoc [Internet]. 1988;259:3269.
- Casteels-Van Daele M, Wijndaele LHK. Intravenous Immune Globulin and Acute Aseptic Meningitis. N Engl J Med. 1990;323:614–615. . Internet
- Thomas MJ, Misbah SA, Chapel HM, et al. Hemolysis after high-dose intravenous Ig [letter]. Blood. 1993;82:3789.
- Reinhart W, Berchtold P. Effect of high-dose intravenous immunoglobulin therapy on blood rheology. Lancet. [ Internet]. 1992;339:662–664. Available from: https://linkinghub.elsevier.com/retrieve/pii/014067369290806E.
- Copelan E, Strohm P, Kennedy M, et al. Hemolysis following intravenous immune globulin therapy. Transfusion [Internet]. 1986;26:410–412.
- Kessary-Shoham H, Levy Y, Shoenfeld Y, et al. In vivoAdministration of Intravenous Immunoglobulin (IVIg) can Lead to Enhanced Erythrocyte Sequestration. J Autoimmun. [ Internet]. 1999;13:129–135. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0896841199903025.
- Sharma A, Aryal D. Hemolysis induced cross-matching difficulty with intravenous immunoglobulin: a case report. J Med Case Rep [Internet]. 2018;12:245.
- Mallick R, Hubsch A, Barnes DG. Hemolytic adverse effects of intravenous immunoglobulin: modeling predicts risk reduction with anti-A/B immunoaffinity chromatography and to a lesser extent with anti-A donor screening. Transfusion. 2018;58:2752–2756.
- Berger-Achituv S, Ellis MH, Curtis BR, et al. Transfusion-related acute lung injury following intravenous anti-D administration in an adolescent. Am J Hematol [Internet]. 2008;83:676–678.
- Voulgari PV, Paschou S, Svarna E, et al. Transfusion-related Acute Lung Injury During Intravenous Immunoglobulin Treatment. J Rheumatol [Internet]. 2010;37:190–191.
- Gupta V, Gupta P, Yadav TP. Transfusion related acute lung injury with intravenous immunoglobulin. Indian Pediatr. [ Internet]. 2011;48:807–808. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22080684.
- Quest GR, Gaal H, Clarke G, et al. Transfusion-related acute lung injury after transfusion of pooled immune globulin: a case report. Transfusion [Internet]. 2014;54:3088–3091.
- Reddy DRS, Guru PK, Blessing MM, et al. Transfusion-Related Acute Lung Injury After IVIG for Myasthenic Crisis. Neurocrit Care [Internet]. 2015;23:259–261.
- Rizk A, Gorson KC, Kenney L, et al. Transfusion-related acute lung injury after the infusion of IVIG. Transfusion [Internet]. 2001;41:264–268.
- Stoclin A, Delbos F, Dauriat G, et al. Transfusion-related acute lung injury after intravenous immunoglobulin treatment in a lung transplant recipient. Vox Sang. [ Internet]. 2013;104:175–178. .
- Vlaar APJ, Juffermans NP. Transfusion-related acute lung injury: A clinical review. Lancet. 2013;382:984–994.
- CytoGam® (Cytomegalovirus Immune Globulin Intravenous) [package insert]. Bern, Switzerland: CSL Behring AG; 2007.
- Smith C, Beagley LRehan S, et al. Autologous Adoptive T-cell Therapy for Recurrent or Drug-resistant Cytomegalovirus Complications in Solid Organ Transplant Recipients: A Single-arm Open-label Phase I Clinical Trial. Clin. Infect. Dis. [ Internet]. 2019;68:632–640. Available from: https://academic.oup.com/cid/article/68/4/632/5049442
- Neuenhahn M, Albrecht J, Odendahl M, et al. Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT. Leukemia. [ Internet]. 2017;31:2161–2171. Available from: http://www.nature.com/articles/leu201716.
- Holmes-Liew C-L, Holmes M, Beagley L, et al. Adoptive T-cell immunotherapy for ganciclovir-resistant CMV disease after lung transplantation. Clin Transl Immunol. [ Internet]. 2015;4:e35. .
- Macesic N, Langsford D, Nicholls K, et al. Adoptive T Cell Immunotherapy for Treatment of Ganciclovir-Resistant Cytomegalovirus Disease in a Renal Transplant Recipient. Am J Transplant [Internet]. 2015;15:827–832.
- Blyth E, Clancy L, Simms R, et al. Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation. Blood. 2013;121:3745–3758.
- Roemhild A, Reinke P. Virus-specific T-cell therapy in solid organ transplantation. Transpl Int. 2016;29:515–526.
- Kaeuferle T, Krauss R, Blaeschke F, et al. Strategies of adoptive T -cell transfer to treat refractory viral infections post allogeneic stem cell transplantation. J Hematol Oncol. 2019;12:13.
- Baugh KA, Tzannou I, Leen AM. Infusion of cytotoxic T lymphocytes for the treatment of viral infections in hematopoetic stem cell transplant patients. Curr Opin Infect Dis. 2018;31:1.